BRIEF-Syros says on track to begin Phase 1 trial of SY-1365 in Q2
April 3 Syros Pharmaceuticals Inc:
* Syros Pharmaceuticals Inc - new data demonstrate SY-1365 inhibits tumor growth in In Vivo models of triple negative breast cancer
* Syros Pharmaceuticals Inc - new data demonstrate sy-1365 inhibits tumor growth in in vivo models of triple negative breast cancer
* Syros Pharma - new data show sy-1365 has anti-proliferative activity in additional cancer cells, including ovarian and small cell lung cancers
* Syros Pharmaceuticals Inc - on track to begin a Phase 1 clinical trial of SY-1365 in Q2 Source text for Eikon: Further company coverage: